nodes	percent_of_prediction	percent_of_DWPC	metapath
Nafarelin—Gonadotropin Releasing Hormone Receptor Agonists—Goserelin—breast cancer	0.377	1	CiPCiCtD
Nafarelin—Goserelin—breast cancer	0.242	1	CrCtD
Nafarelin—GNRHR—Goserelin—breast cancer	0.163	1	CbGbCtD
Nafarelin—Cetrorelix—Goserelin—breast cancer	0.036	0.223	CrCrCtD
Nafarelin—Pentagastrin—Goserelin—breast cancer	0.036	0.223	CrCrCtD
Nafarelin—Degarelix—Goserelin—breast cancer	0.036	0.223	CrCrCtD
Nafarelin—Ceruletide—Goserelin—breast cancer	0.0311	0.193	CrCrCtD
Nafarelin—Gonadorelin—Goserelin—breast cancer	0.0225	0.139	CrCrCtD
Nafarelin—Pentagastrin—BCHE—breast cancer	0.000179	0.61	CrCbGaD
Nafarelin—Desmopressin—PTGS1—breast cancer	7.31e-05	0.248	CrCbGaD
Nafarelin—GNRHR—GPCR ligand binding—CXCL3—breast cancer	6.15e-05	0.00921	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CCL27—breast cancer	6.15e-05	0.00921	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL20—breast cancer	5.84e-05	0.00874	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRB—breast cancer	5.79e-05	0.00867	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—LPAR1—breast cancer	5.66e-05	0.00847	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CNR2—breast cancer	5.21e-05	0.00779	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—AGTR1—breast cancer	5.2e-05	0.00778	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—ITPR1—breast cancer	4.66e-05	0.00698	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—breast cancer	4.65e-05	0.00696	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL2—breast cancer	4.48e-05	0.0067	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGTR2—breast cancer	4.48e-05	0.0067	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CCL20—breast cancer	4.45e-05	0.00666	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—GPER1—breast cancer	4.38e-05	0.00655	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—LPAR1—breast cancer	4.31e-05	0.00645	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—EDNRB—breast cancer	4.29e-05	0.00642	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—STARD8—breast cancer	4.28e-05	0.00641	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—NMBR—breast cancer	4.2e-05	0.00628	CbGpPWpGaD
Nafarelin—Desmopressin—PTGS2—breast cancer	4.18e-05	0.142	CrCbGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—ITPR1—breast cancer	4.17e-05	0.00624	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—breast cancer	4.14e-05	0.0062	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—GPER1—breast cancer	3.97e-05	0.00595	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CNR2—breast cancer	3.96e-05	0.00593	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PTGER1—breast cancer	3.9e-05	0.00584	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—NMBR—breast cancer	3.81e-05	0.0057	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL12—breast cancer	3.81e-05	0.0057	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCR4—breast cancer	3.81e-05	0.0057	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—WNT1—breast cancer	3.73e-05	0.00558	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PTGER1—breast cancer	3.54e-05	0.0053	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CCL27—breast cancer	3.48e-05	0.0052	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CXCL3—breast cancer	3.48e-05	0.0052	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PDE2A—breast cancer	3.48e-05	0.0052	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGTR1—breast cancer	3.44e-05	0.00515	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CXCL2—breast cancer	3.41e-05	0.0051	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—AGTR2—breast cancer	3.41e-05	0.0051	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—PTHLH—breast cancer	3.37e-05	0.00505	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—EDNRB—breast cancer	3.26e-05	0.00489	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—WNT10B—breast cancer	3.24e-05	0.00485	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CXCL3—breast cancer	3.16e-05	0.00473	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CCL27—breast cancer	3.16e-05	0.00473	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PDE2A—breast cancer	3.16e-05	0.00473	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CALCA—breast cancer	2.97e-05	0.00444	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CXCL12—breast cancer	2.9e-05	0.00434	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CXCR4—breast cancer	2.9e-05	0.00434	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—AGTR1—breast cancer	2.62e-05	0.00392	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—RGS2—breast cancer	2.54e-05	0.0038	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CCL20—breast cancer	2.51e-05	0.00376	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCDC88C—breast cancer	2.46e-05	0.00368	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—LGR6—breast cancer	2.46e-05	0.00368	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—LPAR1—breast cancer	2.43e-05	0.00364	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—GPER1—breast cancer	2.35e-05	0.00351	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SFRP1—breast cancer	2.35e-05	0.00351	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—RGS2—breast cancer	2.31e-05	0.00346	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PDE4D—breast cancer	2.3e-05	0.00344	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CCL20—breast cancer	2.28e-05	0.00342	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—breast cancer	2.27e-05	0.0034	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NMBR—breast cancer	2.25e-05	0.00337	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CNR2—breast cancer	2.24e-05	0.00335	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—LPAR1—breast cancer	2.21e-05	0.00331	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HEYL—breast cancer	2.09e-05	0.00313	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CUL5—breast cancer	2.09e-05	0.00313	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PTGER1—breast cancer	2.09e-05	0.00313	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PDE4D—breast cancer	2.09e-05	0.00312	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CNR2—breast cancer	2.03e-05	0.00305	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—RSPO3—breast cancer	1.97e-05	0.00294	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CXCL2—breast cancer	1.93e-05	0.00288	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—AGTR2—breast cancer	1.93e-05	0.00288	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—WWOX—breast cancer	1.91e-05	0.00286	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—WNT10B—breast cancer	1.91e-05	0.00286	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—WNT1—breast cancer	1.91e-05	0.00286	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PTHLH—breast cancer	1.9e-05	0.00285	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCL27—breast cancer	1.87e-05	0.00279	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—INHBB—breast cancer	1.87e-05	0.00279	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PDE2A—breast cancer	1.87e-05	0.00279	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CXCL3—breast cancer	1.87e-05	0.00279	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—EDNRB—breast cancer	1.84e-05	0.00276	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—DLL4—breast cancer	1.78e-05	0.00266	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—BMPR2—breast cancer	1.78e-05	0.00266	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—AGTR2—breast cancer	1.75e-05	0.00262	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CXCL2—breast cancer	1.75e-05	0.00262	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PTHLH—breast cancer	1.73e-05	0.00259	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CDH5—breast cancer	1.71e-05	0.00255	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CALCA—breast cancer	1.68e-05	0.00251	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—EDNRB—breast cancer	1.68e-05	0.00251	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SFRP2—breast cancer	1.67e-05	0.0025	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PRLR—breast cancer	1.64e-05	0.00246	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CXCR4—breast cancer	1.64e-05	0.00245	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CXCL12—breast cancer	1.64e-05	0.00245	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—breast cancer	1.64e-05	0.00245	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—GLI2—breast cancer	1.59e-05	0.00237	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—VCP—breast cancer	1.59e-05	0.00237	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—breast cancer	1.58e-05	0.00236	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—LEPR—breast cancer	1.56e-05	0.00234	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—breast cancer	1.56e-05	0.00233	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CALCA—breast cancer	1.52e-05	0.00228	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—PIK3CA—breast cancer	1.51e-05	0.00226	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CXCL12—breast cancer	1.49e-05	0.00223	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CXCR4—breast cancer	1.49e-05	0.00223	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—AGTR1—breast cancer	1.48e-05	0.00222	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—breast cancer	1.47e-05	0.0022	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—ARHGDIA—breast cancer	1.45e-05	0.00217	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—FST—breast cancer	1.41e-05	0.00212	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HEY2—breast cancer	1.4e-05	0.00209	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—RPS6KB2—breast cancer	1.38e-05	0.00206	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—RGS2—breast cancer	1.36e-05	0.00204	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—breast cancer	1.35e-05	0.00202	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCL20—breast cancer	1.35e-05	0.00202	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—AGTR1—breast cancer	1.35e-05	0.00201	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—ITPR1—breast cancer	1.33e-05	0.00199	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—LPAR1—breast cancer	1.31e-05	0.00195	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TLE3—breast cancer	1.31e-05	0.00195	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HEY1—breast cancer	1.29e-05	0.00193	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—DLL1—breast cancer	1.27e-05	0.0019	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—breast cancer	1.25e-05	0.00187	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HIST1H2BK—breast cancer	1.24e-05	0.00186	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HIST1H2BC—breast cancer	1.24e-05	0.00186	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—GRB7—breast cancer	1.23e-05	0.00185	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PDE4D—breast cancer	1.23e-05	0.00185	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CSF2—breast cancer	1.23e-05	0.00184	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TAB2—breast cancer	1.21e-05	0.00181	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—ITPR1—breast cancer	1.21e-05	0.00181	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CNR2—breast cancer	1.2e-05	0.0018	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CXCL8—breast cancer	1.2e-05	0.0018	CbGpPWpGaD
Nafarelin—Mental disorder—Docetaxel—breast cancer	1.2e-05	0.00024	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—MMP3—breast cancer	1.2e-05	0.00179	CbGpPWpGaD
Nafarelin—Arthralgia—Paclitaxel—breast cancer	1.2e-05	0.00024	CcSEcCtD
Nafarelin—Chest pain—Paclitaxel—breast cancer	1.2e-05	0.00024	CcSEcCtD
Nafarelin—Myalgia—Paclitaxel—breast cancer	1.2e-05	0.00024	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—breast cancer	1.2e-05	0.00179	CbGpPWpGaD
Nafarelin—Headache—Goserelin—breast cancer	1.19e-05	0.000239	CcSEcCtD
Nafarelin—Malnutrition—Docetaxel—breast cancer	1.19e-05	0.000239	CcSEcCtD
Nafarelin—Decreased appetite—Gemcitabine—breast cancer	1.19e-05	0.000239	CcSEcCtD
Nafarelin—Nausea—Tamoxifen—breast cancer	1.18e-05	0.000237	CcSEcCtD
Nafarelin—Gastritis—Epirubicin—breast cancer	1.18e-05	0.000237	CcSEcCtD
Nafarelin—Muscular weakness—Epirubicin—breast cancer	1.18e-05	0.000236	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—DKK1—breast cancer	1.17e-05	0.00176	CbGpPWpGaD
Nafarelin—Constipation—Gemcitabine—breast cancer	1.17e-05	0.000235	CcSEcCtD
Nafarelin—Decreased appetite—Fluorouracil—breast cancer	1.17e-05	0.000235	CcSEcCtD
Nafarelin—Alopecia—Capecitabine—breast cancer	1.17e-05	0.000235	CcSEcCtD
Nafarelin—Mood swings—Doxorubicin—breast cancer	1.17e-05	0.000234	CcSEcCtD
Nafarelin—Asthenia—Thiotepa—breast cancer	1.17e-05	0.000234	CcSEcCtD
Nafarelin—Diarrhoea—Vinorelbine—breast cancer	1.17e-05	0.000234	CcSEcCtD
Nafarelin—Dysgeusia—Docetaxel—breast cancer	1.17e-05	0.000234	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—VEGFC—breast cancer	1.16e-05	0.00174	CbGpPWpGaD
Nafarelin—Abdominal distension—Epirubicin—breast cancer	1.16e-05	0.000233	CcSEcCtD
Nafarelin—Mental disorder—Capecitabine—breast cancer	1.16e-05	0.000233	CcSEcCtD
Nafarelin—Nausea—Melphalan—breast cancer	1.16e-05	0.000232	CcSEcCtD
Nafarelin—Malnutrition—Capecitabine—breast cancer	1.15e-05	0.000231	CcSEcCtD
Nafarelin—Dysuria—Methotrexate—breast cancer	1.15e-05	0.000231	CcSEcCtD
Nafarelin—Pruritus—Thiotepa—breast cancer	1.15e-05	0.000231	CcSEcCtD
Nafarelin—Oedema—Paclitaxel—breast cancer	1.15e-05	0.00023	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—JAG2—breast cancer	1.15e-05	0.00172	CbGpPWpGaD
Nafarelin—Dry skin—Doxorubicin—breast cancer	1.13e-05	0.000227	CcSEcCtD
Nafarelin—Nausea—Goserelin—breast cancer	1.13e-05	0.000227	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—WNT1—breast cancer	1.13e-05	0.00169	CbGpPWpGaD
Nafarelin—Dysgeusia—Capecitabine—breast cancer	1.13e-05	0.000226	CcSEcCtD
Nafarelin—Shock—Paclitaxel—breast cancer	1.13e-05	0.000226	CcSEcCtD
Nafarelin—Dizziness—Vinorelbine—breast cancer	1.13e-05	0.000226	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—PLA2G4A—breast cancer	1.13e-05	0.00169	CbGpPWpGaD
Nafarelin—Urticaria—Mitoxantrone—breast cancer	1.12e-05	0.000224	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CSF2—breast cancer	1.11e-05	0.00167	CbGpPWpGaD
Nafarelin—Diarrhoea—Thiotepa—breast cancer	1.11e-05	0.000223	CcSEcCtD
Nafarelin—Hyperhidrosis—Paclitaxel—breast cancer	1.11e-05	0.000222	CcSEcCtD
Nafarelin—Depression—Methotrexate—breast cancer	1.1e-05	0.00022	CcSEcCtD
Nafarelin—Anorexia—Paclitaxel—breast cancer	1.09e-05	0.000219	CcSEcCtD
Nafarelin—Gastritis—Doxorubicin—breast cancer	1.09e-05	0.000219	CcSEcCtD
Nafarelin—Muscular weakness—Doxorubicin—breast cancer	1.09e-05	0.000218	CcSEcCtD
Nafarelin—Vomiting—Vinorelbine—breast cancer	1.08e-05	0.000217	CcSEcCtD
Nafarelin—Dysuria—Epirubicin—breast cancer	1.08e-05	0.000216	CcSEcCtD
Nafarelin—Dizziness—Thiotepa—breast cancer	1.08e-05	0.000216	CcSEcCtD
Nafarelin—Rash—Vinorelbine—breast cancer	1.08e-05	0.000216	CcSEcCtD
Nafarelin—Dermatitis—Vinorelbine—breast cancer	1.07e-05	0.000215	CcSEcCtD
Nafarelin—Abdominal distension—Doxorubicin—breast cancer	1.07e-05	0.000215	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—NOTCH4—breast cancer	1.07e-05	0.0016	CbGpPWpGaD
Nafarelin—Urticaria—Fluorouracil—breast cancer	1.07e-05	0.000215	CcSEcCtD
Nafarelin—Headache—Vinorelbine—breast cancer	1.07e-05	0.000214	CcSEcCtD
Nafarelin—Conjunctivitis—Methotrexate—breast cancer	1.07e-05	0.000214	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—GZMB—breast cancer	1.06e-05	0.00159	CbGpPWpGaD
Nafarelin—Palpitations—Docetaxel—breast cancer	1.05e-05	0.000211	CcSEcCtD
Nafarelin—Weight increased—Epirubicin—breast cancer	1.05e-05	0.00021	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Paclitaxel—breast cancer	1.05e-05	0.00021	CcSEcCtD
Nafarelin—Weight decreased—Epirubicin—breast cancer	1.04e-05	0.000209	CcSEcCtD
Nafarelin—Insomnia—Paclitaxel—breast cancer	1.04e-05	0.000208	CcSEcCtD
Nafarelin—Epistaxis—Methotrexate—breast cancer	1.04e-05	0.000208	CcSEcCtD
Nafarelin—Vertigo—Capecitabine—breast cancer	1.04e-05	0.000208	CcSEcCtD
Nafarelin—Vomiting—Thiotepa—breast cancer	1.04e-05	0.000208	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CXCL2—breast cancer	1.03e-05	0.00155	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AGTR2—breast cancer	1.03e-05	0.00155	CbGpPWpGaD
Nafarelin—Convulsion—Docetaxel—breast cancer	1.03e-05	0.000207	CcSEcCtD
Nafarelin—Paraesthesia—Paclitaxel—breast cancer	1.03e-05	0.000206	CcSEcCtD
Nafarelin—Rash—Thiotepa—breast cancer	1.03e-05	0.000206	CcSEcCtD
Nafarelin—Dermatitis—Thiotepa—breast cancer	1.03e-05	0.000206	CcSEcCtD
Nafarelin—Dyspnoea—Paclitaxel—breast cancer	1.02e-05	0.000205	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PTHLH—breast cancer	1.02e-05	0.00153	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—BMP2—breast cancer	1.02e-05	0.00153	CbGpPWpGaD
Nafarelin—Headache—Thiotepa—breast cancer	1.02e-05	0.000205	CcSEcCtD
Nafarelin—Palpitations—Capecitabine—breast cancer	1.02e-05	0.000204	CcSEcCtD
Nafarelin—Myalgia—Docetaxel—breast cancer	1.01e-05	0.000203	CcSEcCtD
Nafarelin—Arthralgia—Docetaxel—breast cancer	1.01e-05	0.000203	CcSEcCtD
Nafarelin—Chest pain—Docetaxel—breast cancer	1.01e-05	0.000203	CcSEcCtD
Nafarelin—Nausea—Vinorelbine—breast cancer	1.01e-05	0.000203	CcSEcCtD
Nafarelin—Asthenia—Mitoxantrone—breast cancer	1.01e-05	0.000202	CcSEcCtD
Nafarelin—Asthenia—Irinotecan—breast cancer	1.01e-05	0.000202	CcSEcCtD
Nafarelin—Conjunctivitis—Epirubicin—breast cancer	1e-05	0.0002	CcSEcCtD
Nafarelin—Dysuria—Doxorubicin—breast cancer	9.98e-06	0.0002	CcSEcCtD
Nafarelin—Decreased appetite—Paclitaxel—breast cancer	9.97e-06	0.0002	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—EDNRB—breast cancer	9.9e-06	0.00148	CbGpPWpGaD
Nafarelin—Asthenia—Gemcitabine—breast cancer	9.83e-06	0.000197	CcSEcCtD
Nafarelin—Myalgia—Capecitabine—breast cancer	9.82e-06	0.000197	CcSEcCtD
Nafarelin—Chest pain—Capecitabine—breast cancer	9.82e-06	0.000197	CcSEcCtD
Nafarelin—Arthralgia—Capecitabine—breast cancer	9.82e-06	0.000197	CcSEcCtD
Nafarelin—Constipation—Paclitaxel—breast cancer	9.81e-06	0.000197	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PGR—breast cancer	9.8e-06	0.00147	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—THBS1—breast cancer	9.75e-06	0.00146	CbGpPWpGaD
Nafarelin—Oedema—Docetaxel—breast cancer	9.72e-06	0.000195	CcSEcCtD
Nafarelin—Weight increased—Doxorubicin—breast cancer	9.71e-06	0.000195	CcSEcCtD
Nafarelin—Epistaxis—Epirubicin—breast cancer	9.7e-06	0.000194	CcSEcCtD
Nafarelin—Pruritus—Gemcitabine—breast cancer	9.7e-06	0.000194	CcSEcCtD
Nafarelin—Nausea—Thiotepa—breast cancer	9.68e-06	0.000194	CcSEcCtD
Nafarelin—Weight decreased—Doxorubicin—breast cancer	9.66e-06	0.000194	CcSEcCtD
Nafarelin—Sinusitis—Epirubicin—breast cancer	9.65e-06	0.000193	CcSEcCtD
Nafarelin—Diarrhoea—Mitoxantrone—breast cancer	9.63e-06	0.000193	CcSEcCtD
Nafarelin—Diarrhoea—Irinotecan—breast cancer	9.63e-06	0.000193	CcSEcCtD
Nafarelin—Shock—Docetaxel—breast cancer	9.57e-06	0.000192	CcSEcCtD
Nafarelin—Pruritus—Fluorouracil—breast cancer	9.53e-06	0.000191	CcSEcCtD
Nafarelin—Oedema—Capecitabine—breast cancer	9.42e-06	0.000189	CcSEcCtD
Nafarelin—Diarrhoea—Gemcitabine—breast cancer	9.38e-06	0.000188	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—FLT1—breast cancer	9.31e-06	0.00139	CbGpPWpGaD
Nafarelin—Dizziness—Irinotecan—breast cancer	9.3e-06	0.000186	CcSEcCtD
Nafarelin—Anorexia—Docetaxel—breast cancer	9.27e-06	0.000186	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—SQSTM1—breast cancer	9.26e-06	0.00139	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—FGF3—breast cancer	9.26e-06	0.00139	CbGpPWpGaD
Nafarelin—Shock—Capecitabine—breast cancer	9.26e-06	0.000186	CcSEcCtD
Nafarelin—Rhinitis—Epirubicin—breast cancer	9.26e-06	0.000186	CcSEcCtD
Nafarelin—Conjunctivitis—Doxorubicin—breast cancer	9.25e-06	0.000185	CcSEcCtD
Nafarelin—Diarrhoea—Fluorouracil—breast cancer	9.22e-06	0.000185	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CG—breast cancer	9.22e-06	0.00138	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—JAG1—breast cancer	9.15e-06	0.00137	CbGpPWpGaD
Nafarelin—Urticaria—Paclitaxel—breast cancer	9.11e-06	0.000183	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PARP1—breast cancer	9.11e-06	0.00136	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NOTCH3—breast cancer	9.11e-06	0.00136	CbGpPWpGaD
Nafarelin—Hyperhidrosis—Capecitabine—breast cancer	9.1e-06	0.000182	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CALCA—breast cancer	9e-06	0.00135	CbGpPWpGaD
Nafarelin—Epistaxis—Doxorubicin—breast cancer	8.98e-06	0.00018	CcSEcCtD
Nafarelin—Anorexia—Capecitabine—breast cancer	8.98e-06	0.00018	CcSEcCtD
Nafarelin—Vomiting—Irinotecan—breast cancer	8.94e-06	0.000179	CcSEcCtD
Nafarelin—Vomiting—Mitoxantrone—breast cancer	8.94e-06	0.000179	CcSEcCtD
Nafarelin—Sinusitis—Doxorubicin—breast cancer	8.93e-06	0.000179	CcSEcCtD
Nafarelin—Dizziness—Fluorouracil—breast cancer	8.91e-06	0.000179	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—RPS6—breast cancer	8.89e-06	0.00133	CbGpPWpGaD
Nafarelin—Rash—Irinotecan—breast cancer	8.87e-06	0.000178	CcSEcCtD
Nafarelin—Rash—Mitoxantrone—breast cancer	8.87e-06	0.000178	CcSEcCtD
Nafarelin—Dermatitis—Irinotecan—breast cancer	8.86e-06	0.000178	CcSEcCtD
Nafarelin—Dermatitis—Mitoxantrone—breast cancer	8.86e-06	0.000178	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Docetaxel—breast cancer	8.86e-06	0.000178	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—FGF4—breast cancer	8.82e-06	0.00132	CbGpPWpGaD
Nafarelin—Headache—Mitoxantrone—breast cancer	8.81e-06	0.000177	CcSEcCtD
Nafarelin—Headache—Irinotecan—breast cancer	8.81e-06	0.000177	CcSEcCtD
Nafarelin—Insomnia—Docetaxel—breast cancer	8.8e-06	0.000176	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CXCL12—breast cancer	8.79e-06	0.00132	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CXCR4—breast cancer	8.79e-06	0.00132	CbGpPWpGaD
Nafarelin—Paraesthesia—Docetaxel—breast cancer	8.73e-06	0.000175	CcSEcCtD
Nafarelin—Alopecia—Methotrexate—breast cancer	8.72e-06	0.000175	CcSEcCtD
Nafarelin—Vomiting—Gemcitabine—breast cancer	8.71e-06	0.000175	CcSEcCtD
Nafarelin—Dyspnoea—Docetaxel—breast cancer	8.67e-06	0.000174	CcSEcCtD
Nafarelin—Mental disorder—Methotrexate—breast cancer	8.64e-06	0.000173	CcSEcCtD
Nafarelin—Rash—Gemcitabine—breast cancer	8.64e-06	0.000173	CcSEcCtD
Nafarelin—Dermatitis—Gemcitabine—breast cancer	8.63e-06	0.000173	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PAK1—breast cancer	8.63e-06	0.00129	CbGpPWpGaD
Nafarelin—Malnutrition—Methotrexate—breast cancer	8.59e-06	0.000172	CcSEcCtD
Nafarelin—Headache—Gemcitabine—breast cancer	8.58e-06	0.000172	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Capecitabine—breast cancer	8.58e-06	0.000172	CcSEcCtD
Nafarelin—Vomiting—Fluorouracil—breast cancer	8.57e-06	0.000172	CcSEcCtD
Nafarelin—Rhinitis—Doxorubicin—breast cancer	8.56e-06	0.000172	CcSEcCtD
Nafarelin—Insomnia—Capecitabine—breast cancer	8.52e-06	0.000171	CcSEcCtD
Nafarelin—Rash—Fluorouracil—breast cancer	8.5e-06	0.00017	CcSEcCtD
Nafarelin—Dermatitis—Fluorouracil—breast cancer	8.49e-06	0.00017	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—TCF7L2—breast cancer	8.47e-06	0.00127	CbGpPWpGaD
Nafarelin—Paraesthesia—Capecitabine—breast cancer	8.45e-06	0.000169	CcSEcCtD
Nafarelin—Decreased appetite—Docetaxel—breast cancer	8.45e-06	0.000169	CcSEcCtD
Nafarelin—Headache—Fluorouracil—breast cancer	8.44e-06	0.000169	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—AKT2—breast cancer	8.43e-06	0.00126	CbGpPWpGaD
Nafarelin—Dysgeusia—Methotrexate—breast cancer	8.41e-06	0.000169	CcSEcCtD
Nafarelin—Dyspnoea—Capecitabine—breast cancer	8.39e-06	0.000168	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CG—breast cancer	8.37e-06	0.00125	CbGpPWpGaD
Nafarelin—Nausea—Mitoxantrone—breast cancer	8.36e-06	0.000167	CcSEcCtD
Nafarelin—Nausea—Irinotecan—breast cancer	8.36e-06	0.000167	CcSEcCtD
Nafarelin—Constipation—Docetaxel—breast cancer	8.32e-06	0.000167	CcSEcCtD
Nafarelin—Asthenia—Paclitaxel—breast cancer	8.23e-06	0.000165	CcSEcCtD
Nafarelin—Decreased appetite—Capecitabine—breast cancer	8.18e-06	0.000164	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—NOTCH2—breast cancer	8.17e-06	0.00122	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HSP90AA1—breast cancer	8.17e-06	0.00122	CbGpPWpGaD
Nafarelin—Alopecia—Epirubicin—breast cancer	8.16e-06	0.000164	CcSEcCtD
Nafarelin—Nausea—Gemcitabine—breast cancer	8.14e-06	0.000163	CcSEcCtD
Nafarelin—Pruritus—Paclitaxel—breast cancer	8.12e-06	0.000163	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CD—breast cancer	8.1e-06	0.00121	CbGpPWpGaD
Nafarelin—Mental disorder—Epirubicin—breast cancer	8.09e-06	0.000162	CcSEcCtD
Nafarelin—Constipation—Capecitabine—breast cancer	8.05e-06	0.000161	CcSEcCtD
Nafarelin—Malnutrition—Epirubicin—breast cancer	8.04e-06	0.000161	CcSEcCtD
Nafarelin—Nausea—Fluorouracil—breast cancer	8e-06	0.00016	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PRL—breast cancer	7.95e-06	0.00119	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AGTR1—breast cancer	7.95e-06	0.00119	CbGpPWpGaD
Nafarelin—Tension—Epirubicin—breast cancer	7.89e-06	0.000158	CcSEcCtD
Nafarelin—Dysgeusia—Epirubicin—breast cancer	7.87e-06	0.000158	CcSEcCtD
Nafarelin—Diarrhoea—Paclitaxel—breast cancer	7.85e-06	0.000157	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—STK11—breast cancer	7.83e-06	0.00117	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—ADAM10—breast cancer	7.83e-06	0.00117	CbGpPWpGaD
Nafarelin—Nervousness—Epirubicin—breast cancer	7.81e-06	0.000156	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PLG—breast cancer	7.74e-06	0.00116	CbGpPWpGaD
Nafarelin—Vertigo—Methotrexate—breast cancer	7.72e-06	0.000155	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—AKT2—breast cancer	7.66e-06	0.00115	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—FGF10—breast cancer	7.62e-06	0.00114	CbGpPWpGaD
Nafarelin—Dizziness—Paclitaxel—breast cancer	7.59e-06	0.000152	CcSEcCtD
Nafarelin—Alopecia—Doxorubicin—breast cancer	7.55e-06	0.000151	CcSEcCtD
Nafarelin—Mental disorder—Doxorubicin—breast cancer	7.48e-06	0.00015	CcSEcCtD
Nafarelin—Urticaria—Capecitabine—breast cancer	7.48e-06	0.00015	CcSEcCtD
Nafarelin—Convulsion—Methotrexate—breast cancer	7.44e-06	0.000149	CcSEcCtD
Nafarelin—Malnutrition—Doxorubicin—breast cancer	7.44e-06	0.000149	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CD—breast cancer	7.36e-06	0.0011	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PDGFA—breast cancer	7.35e-06	0.0011	CbGpPWpGaD
Nafarelin—Chest pain—Methotrexate—breast cancer	7.31e-06	0.000147	CcSEcCtD
Nafarelin—Myalgia—Methotrexate—breast cancer	7.31e-06	0.000147	CcSEcCtD
Nafarelin—Arthralgia—Methotrexate—breast cancer	7.31e-06	0.000147	CcSEcCtD
Nafarelin—Tension—Doxorubicin—breast cancer	7.3e-06	0.000146	CcSEcCtD
Nafarelin—Vomiting—Paclitaxel—breast cancer	7.29e-06	0.000146	CcSEcCtD
Nafarelin—Dysgeusia—Doxorubicin—breast cancer	7.28e-06	0.000146	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—TGFBR2—breast cancer	7.25e-06	0.00108	CbGpPWpGaD
Nafarelin—Rash—Paclitaxel—breast cancer	7.23e-06	0.000145	CcSEcCtD
Nafarelin—Dermatitis—Paclitaxel—breast cancer	7.23e-06	0.000145	CcSEcCtD
Nafarelin—Nervousness—Doxorubicin—breast cancer	7.22e-06	0.000145	CcSEcCtD
Nafarelin—Vertigo—Epirubicin—breast cancer	7.22e-06	0.000145	CcSEcCtD
Nafarelin—Headache—Paclitaxel—breast cancer	7.19e-06	0.000144	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—ITPR1—breast cancer	7.13e-06	0.00107	CbGpPWpGaD
Nafarelin—Palpitations—Epirubicin—breast cancer	7.1e-06	0.000142	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—ERBB4—breast cancer	7.08e-06	0.00106	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—STAT5A—breast cancer	7.08e-06	0.00106	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MMP3—breast cancer	7.08e-06	0.00106	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CB—breast cancer	7.06e-06	0.00106	CbGpPWpGaD
Nafarelin—Asthenia—Docetaxel—breast cancer	6.98e-06	0.00014	CcSEcCtD
Nafarelin—Convulsion—Epirubicin—breast cancer	6.96e-06	0.00014	CcSEcCtD
Nafarelin—Pruritus—Docetaxel—breast cancer	6.88e-06	0.000138	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—SMAD4—breast cancer	6.86e-06	0.00103	CbGpPWpGaD
Nafarelin—Arthralgia—Epirubicin—breast cancer	6.84e-06	0.000137	CcSEcCtD
Nafarelin—Chest pain—Epirubicin—breast cancer	6.84e-06	0.000137	CcSEcCtD
Nafarelin—Myalgia—Epirubicin—breast cancer	6.84e-06	0.000137	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—IGF1R—breast cancer	6.82e-06	0.00102	CbGpPWpGaD
Nafarelin—Nausea—Paclitaxel—breast cancer	6.82e-06	0.000137	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—CXCL8—breast cancer	6.79e-06	0.00102	CbGpPWpGaD
Nafarelin—Hyperhidrosis—Methotrexate—breast cancer	6.78e-06	0.000136	CcSEcCtD
Nafarelin—Asthenia—Capecitabine—breast cancer	6.76e-06	0.000135	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—HES1—breast cancer	6.7e-06	0.001	CbGpPWpGaD
Nafarelin—Vertigo—Doxorubicin—breast cancer	6.68e-06	0.000134	CcSEcCtD
Nafarelin—Anorexia—Methotrexate—breast cancer	6.68e-06	0.000134	CcSEcCtD
Nafarelin—Pruritus—Capecitabine—breast cancer	6.66e-06	0.000134	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—NCOR1—breast cancer	6.66e-06	0.000997	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PLA2G4A—breast cancer	6.66e-06	0.000997	CbGpPWpGaD
Nafarelin—Diarrhoea—Docetaxel—breast cancer	6.65e-06	0.000133	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—FGF1—breast cancer	6.59e-06	0.000986	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CSF2—breast cancer	6.59e-06	0.000986	CbGpPWpGaD
Nafarelin—Palpitations—Doxorubicin—breast cancer	6.57e-06	0.000132	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—RAF1—breast cancer	6.57e-06	0.000983	CbGpPWpGaD
Nafarelin—Oedema—Epirubicin—breast cancer	6.56e-06	0.000131	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—NRG1—breast cancer	6.54e-06	0.000978	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—H2AFX—breast cancer	6.49e-06	0.000971	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—IL2—breast cancer	6.49e-06	0.000971	CbGpPWpGaD
Nafarelin—Shock—Epirubicin—breast cancer	6.45e-06	0.000129	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—E2F1—breast cancer	6.44e-06	0.000965	CbGpPWpGaD
Nafarelin—Convulsion—Doxorubicin—breast cancer	6.44e-06	0.000129	CcSEcCtD
Nafarelin—Diarrhoea—Capecitabine—breast cancer	6.44e-06	0.000129	CcSEcCtD
Nafarelin—Dizziness—Docetaxel—breast cancer	6.43e-06	0.000129	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CB—breast cancer	6.41e-06	0.00096	CbGpPWpGaD
Nafarelin—Musculoskeletal discomfort—Methotrexate—breast cancer	6.39e-06	0.000128	CcSEcCtD
Nafarelin—Hyperhidrosis—Epirubicin—breast cancer	6.34e-06	0.000127	CcSEcCtD
Nafarelin—Insomnia—Methotrexate—breast cancer	6.34e-06	0.000127	CcSEcCtD
Nafarelin—Chest pain—Doxorubicin—breast cancer	6.33e-06	0.000127	CcSEcCtD
Nafarelin—Myalgia—Doxorubicin—breast cancer	6.33e-06	0.000127	CcSEcCtD
Nafarelin—Arthralgia—Doxorubicin—breast cancer	6.33e-06	0.000127	CcSEcCtD
Nafarelin—Paraesthesia—Methotrexate—breast cancer	6.29e-06	0.000126	CcSEcCtD
Nafarelin—Anorexia—Epirubicin—breast cancer	6.25e-06	0.000125	CcSEcCtD
Nafarelin—Dyspnoea—Methotrexate—breast cancer	6.25e-06	0.000125	CcSEcCtD
Nafarelin—Dizziness—Capecitabine—breast cancer	6.23e-06	0.000125	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—SPP1—breast cancer	6.19e-06	0.000927	CbGpPWpGaD
Nafarelin—Vomiting—Docetaxel—breast cancer	6.18e-06	0.000124	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CXCL8—breast cancer	6.16e-06	0.000923	CbGpPWpGaD
Nafarelin—Rash—Docetaxel—breast cancer	6.13e-06	0.000123	CcSEcCtD
Nafarelin—Dermatitis—Docetaxel—breast cancer	6.13e-06	0.000123	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—ERBB3—breast cancer	6.12e-06	0.000917	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—FGFR2—breast cancer	6.11e-06	0.000915	CbGpPWpGaD
Nafarelin—Decreased appetite—Methotrexate—breast cancer	6.09e-06	0.000122	CcSEcCtD
Nafarelin—Headache—Docetaxel—breast cancer	6.09e-06	0.000122	CcSEcCtD
Nafarelin—Oedema—Doxorubicin—breast cancer	6.07e-06	0.000122	CcSEcCtD
Nafarelin—Vomiting—Capecitabine—breast cancer	5.99e-06	0.00012	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Epirubicin—breast cancer	5.98e-06	0.00012	CcSEcCtD
Nafarelin—Shock—Doxorubicin—breast cancer	5.97e-06	0.00012	CcSEcCtD
Nafarelin—Rash—Capecitabine—breast cancer	5.94e-06	0.000119	CcSEcCtD
Nafarelin—Insomnia—Epirubicin—breast cancer	5.93e-06	0.000119	CcSEcCtD
Nafarelin—Dermatitis—Capecitabine—breast cancer	5.93e-06	0.000119	CcSEcCtD
Nafarelin—Headache—Capecitabine—breast cancer	5.9e-06	0.000118	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—IL2—breast cancer	5.89e-06	0.000882	CbGpPWpGaD
Nafarelin—Paraesthesia—Epirubicin—breast cancer	5.89e-06	0.000118	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—TERT—breast cancer	5.87e-06	0.000879	CbGpPWpGaD
Nafarelin—Hyperhidrosis—Doxorubicin—breast cancer	5.87e-06	0.000118	CcSEcCtD
Nafarelin—Dyspnoea—Epirubicin—breast cancer	5.85e-06	0.000117	CcSEcCtD
Nafarelin—Anorexia—Doxorubicin—breast cancer	5.79e-06	0.000116	CcSEcCtD
Nafarelin—Nausea—Docetaxel—breast cancer	5.78e-06	0.000116	CcSEcCtD
Nafarelin—Decreased appetite—Epirubicin—breast cancer	5.7e-06	0.000114	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—FGFR1—breast cancer	5.7e-06	0.000853	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HIF1A—breast cancer	5.61e-06	0.00084	CbGpPWpGaD
Nafarelin—Constipation—Epirubicin—breast cancer	5.61e-06	0.000112	CcSEcCtD
Nafarelin—Nausea—Capecitabine—breast cancer	5.59e-06	0.000112	CcSEcCtD
Nafarelin—Urticaria—Methotrexate—breast cancer	5.57e-06	0.000112	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Doxorubicin—breast cancer	5.53e-06	0.000111	CcSEcCtD
Nafarelin—Insomnia—Doxorubicin—breast cancer	5.49e-06	0.00011	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—LEP—breast cancer	5.48e-06	0.00082	CbGpPWpGaD
Nafarelin—Paraesthesia—Doxorubicin—breast cancer	5.45e-06	0.000109	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CAV1—breast cancer	5.43e-06	0.000813	CbGpPWpGaD
Nafarelin—Dyspnoea—Doxorubicin—breast cancer	5.41e-06	0.000108	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—KDR—breast cancer	5.37e-06	0.000803	CbGpPWpGaD
Nafarelin—Decreased appetite—Doxorubicin—breast cancer	5.28e-06	0.000106	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—ESR1—breast cancer	5.23e-06	0.000783	CbGpPWpGaD
Nafarelin—Urticaria—Epirubicin—breast cancer	5.21e-06	0.000104	CcSEcCtD
Nafarelin—Constipation—Doxorubicin—breast cancer	5.19e-06	0.000104	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—FN1—breast cancer	5.17e-06	0.000773	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NFKBIA—breast cancer	5.11e-06	0.000764	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NOTCH1—breast cancer	5.06e-06	0.000757	CbGpPWpGaD
Nafarelin—Asthenia—Methotrexate—breast cancer	5.03e-06	0.000101	CcSEcCtD
Nafarelin—Pruritus—Methotrexate—breast cancer	4.96e-06	9.94e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—KIT—breast cancer	4.95e-06	0.00074	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CG—breast cancer	4.95e-06	0.00074	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—APC—breast cancer	4.95e-06	0.00074	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—EGF—breast cancer	4.89e-06	0.000732	CbGpPWpGaD
Nafarelin—Urticaria—Doxorubicin—breast cancer	4.82e-06	9.66e-05	CcSEcCtD
Nafarelin—Diarrhoea—Methotrexate—breast cancer	4.8e-06	9.61e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—MAPK3—breast cancer	4.74e-06	0.000709	CbGpPWpGaD
Nafarelin—Asthenia—Epirubicin—breast cancer	4.71e-06	9.43e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—BRAF—breast cancer	4.65e-06	0.000696	CbGpPWpGaD
Nafarelin—Pruritus—Epirubicin—breast cancer	4.64e-06	9.3e-05	CcSEcCtD
Nafarelin—Dizziness—Methotrexate—breast cancer	4.64e-06	9.29e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—IGF1—breast cancer	4.53e-06	0.000678	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AKT2—breast cancer	4.52e-06	0.000677	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—EGFR—breast cancer	4.51e-06	0.000674	CbGpPWpGaD
Nafarelin—Diarrhoea—Epirubicin—breast cancer	4.49e-06	8.99e-05	CcSEcCtD
Nafarelin—Vomiting—Methotrexate—breast cancer	4.46e-06	8.93e-05	CcSEcCtD
Nafarelin—Rash—Methotrexate—breast cancer	4.42e-06	8.86e-05	CcSEcCtD
Nafarelin—Dermatitis—Methotrexate—breast cancer	4.42e-06	8.85e-05	CcSEcCtD
Nafarelin—Headache—Methotrexate—breast cancer	4.39e-06	8.8e-05	CcSEcCtD
Nafarelin—Asthenia—Doxorubicin—breast cancer	4.35e-06	8.73e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PIK3CD—breast cancer	4.35e-06	0.000651	CbGpPWpGaD
Nafarelin—Dizziness—Epirubicin—breast cancer	4.34e-06	8.69e-05	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CA—breast cancer	4.31e-06	0.000645	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SERPINE1—breast cancer	4.3e-06	0.000644	CbGpPWpGaD
Nafarelin—Pruritus—Doxorubicin—breast cancer	4.29e-06	8.61e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—KRAS—breast cancer	4.26e-06	0.000637	CbGpPWpGaD
Nafarelin—Vomiting—Epirubicin—breast cancer	4.17e-06	8.36e-05	CcSEcCtD
Nafarelin—Nausea—Methotrexate—breast cancer	4.16e-06	8.34e-05	CcSEcCtD
Nafarelin—Diarrhoea—Doxorubicin—breast cancer	4.15e-06	8.32e-05	CcSEcCtD
Nafarelin—Rash—Epirubicin—breast cancer	4.14e-06	8.29e-05	CcSEcCtD
Nafarelin—Dermatitis—Epirubicin—breast cancer	4.13e-06	8.28e-05	CcSEcCtD
Nafarelin—Headache—Epirubicin—breast cancer	4.11e-06	8.24e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—NOS3—breast cancer	4.11e-06	0.000614	CbGpPWpGaD
Nafarelin—Dizziness—Doxorubicin—breast cancer	4.01e-06	8.04e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CA—breast cancer	3.91e-06	0.000585	CbGpPWpGaD
Nafarelin—Nausea—Epirubicin—breast cancer	3.9e-06	7.81e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—MDM2—breast cancer	3.89e-06	0.000583	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—RAF1—breast cancer	3.88e-06	0.000581	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—RELA—breast cancer	3.86e-06	0.000578	CbGpPWpGaD
Nafarelin—Vomiting—Doxorubicin—breast cancer	3.86e-06	7.73e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—ERBB2—breast cancer	3.84e-06	0.000575	CbGpPWpGaD
Nafarelin—Rash—Doxorubicin—breast cancer	3.83e-06	7.67e-05	CcSEcCtD
Nafarelin—Dermatitis—Doxorubicin—breast cancer	3.82e-06	7.66e-05	CcSEcCtD
Nafarelin—Headache—Doxorubicin—breast cancer	3.8e-06	7.62e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—MTOR—breast cancer	3.79e-06	0.000567	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CB—breast cancer	3.79e-06	0.000567	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CXCL8—breast cancer	3.64e-06	0.000545	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—HRAS—breast cancer	3.62e-06	0.000541	CbGpPWpGaD
Nafarelin—Nausea—Doxorubicin—breast cancer	3.61e-06	7.23e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CDKN1B—breast cancer	3.56e-06	0.000532	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—AKT1—breast cancer	3.52e-06	0.000527	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CASP3—breast cancer	3.49e-06	0.000522	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IL2—breast cancer	3.48e-06	0.000521	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—IL6—breast cancer	3.46e-06	0.000518	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCND1—breast cancer	3.39e-06	0.000508	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—JUN—breast cancer	3.39e-06	0.000507	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CTNNB1—breast cancer	3.36e-06	0.000503	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MMP9—breast cancer	3.29e-06	0.000493	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CDKN1A—breast cancer	3.28e-06	0.000491	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PTEN—breast cancer	3.27e-06	0.00049	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MAPK8—breast cancer	3.2e-06	0.000479	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—AKT1—breast cancer	3.19e-06	0.000478	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SRC—breast cancer	3.04e-06	0.000454	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—VEGFA—breast cancer	2.96e-06	0.000443	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—STAT3—breast cancer	2.93e-06	0.000438	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MAPK3—breast cancer	2.8e-06	0.000419	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MYC—breast cancer	2.72e-06	0.000407	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TGFB1—breast cancer	2.71e-06	0.000406	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—EGFR—breast cancer	2.66e-06	0.000398	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—KRAS—breast cancer	2.51e-06	0.000376	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CA—breast cancer	2.31e-06	0.000346	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TP53—breast cancer	2.23e-06	0.000334	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HRAS—breast cancer	2.14e-06	0.00032	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IL6—breast cancer	2.05e-06	0.000306	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AKT1—breast cancer	1.89e-06	0.000282	CbGpPWpGaD
